Basic Information
| LncRNA/CircRNA Name | LINC01133 |
| Synonyms | NA |
| Region | GRCh38_1:159961218-159984750 |
| Ensemble | ENSG00000224259 |
| Refseq | NR_038849 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic ductal adenocarcinoma |
| ICD-0-3 | C25.3 |
| Methods | qPCR etc. |
| Sample | cell lines (BXPC3, CFPAC1, PANC1, and SW1990) |
| Expression Pattern | up-regulated |
| Function Description | LINC01133 expression is higher in PDAC tissues compared to adjacent non-cancerous tissues, and this overexpression is associated with poorer prognosis among the patients. In vitro, a knockdown of LINC01133 substantially decreased PDAC cell proliferation. Tumorigenicity of PDAC cells with the LINC01133 knockdown was significantly impaired in a xenograft model assay. Moreover, we determined that CCAAT/enhancer-binding protein B (C/EBPB) positively regulates LINC01133 expression by binding to the response elements within the LINC01133 promoter. Higher expression of C/EBPB was observed in PDAC tissues, and this overexpression was also associated with the poorer prognosis. Furthermore, the LINC01133 knockdown decreased cyclin G1 (CCNG1) expression. |
| Pubmed ID | 29458145 |
| Year | 2018 |
| Title | The C/EBPB-LINC01133 axis promotes cell proliferation in pancreatic ductal adenocarcinoma through upregulation of CCNG1. |
External Links
| Links for LINC01133 | GenBank HGNC NONCODE |
| Links for pancreatic ductal adenocarcinoma | OMIM COSMIC |